Navigation Links
VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
Date:3/20/2008

- Top Line Data Is Expected to Be Presented in Third Quarter -

SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase 2 trials investigating VIA-2291, the company's lead product candidate.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients who are diagnosed with carotid artery blockage are treated for three months with either VIA-2291 or placebo and then undergo a CEA procedure. The trial will also measure standard serum biomarkers of inflammation to measure reduction of inflammation in treated patients.

"Following analysis of the CEA study data, we expect to have important data with respect to VIA-2291's role in reducing vascular inflammation, as measured in the carotid plaque tissue," said Rebecca A. Taub, M.D., senior vice president of research and development of VIA Pharmaceuti
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July, 29  2014 ISPE—the International Society for ... John Bournas as President and CEO, succeeding ... leave the Society last fall.  Mr. Bournas takes ... the healthcare association industry as well as significant ... clear vision for the expansion of its global ...
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Numotion Names Mike Swinford CEO 2Drew Crawford Announces Launch of PBM365 Media 2
... published in the American Journal of Nephrology -, ... announced that its Phase III data on VAPRISOL was ... Nephrology. In this study,VAPRISOL showed a significant increase in ... life-threatening condition that,occurs when the body,s sodium level falls ...
... Cancer patients at Beaumont,Hospitals are the first in the ... therapy that is painless, faster, more accurate and precise,than ... patented the new,technology, Omnibeam(R). The $3.3-million machine is manufactured ... first patient,was treated on Sept. 10. The painless ...
Cached Medicine Technology:Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5Beaumont Patients 1st to get Next Generation of Radiation Treatment 2
(Date:7/29/2014)... 2014 CHI-California Healthcare Institute today unveiled ... hepatitis C (hep C) epidemic in the U.S., the ... to reduce human suffering. The report examines key data ... hep C, while highlighting the significance of breakthroughs that ... CHI is a nonprofit, public policy research organization, representing ...
(Date:7/29/2014)... The Latin American poultry feed and feed additive ... forecast of revenue. The poultry feed and feed additive market ... and $647.2 million in 2013 to $34,024.0 million and $870.1 ... to 2018, respectively. , To get an idea of the ... the Latin American poultry feed and feed additive market report. ...
(Date:7/29/2014)... The Los Angeles based drug and ... a community program that helps homeless families in the ... the San Fernando Valley Rescue Mission to provide a ... Fernando Valley Rescue Mission offers emergency shelter and services ... Shelter provides housing and basic needs such as food ...
(Date:7/29/2014)... Frank Davis, Activz Founder and CEO, ... add nutrition to their kids’ meals in the ... drivers in kids’ foods market” by Kaylynn Chiarello-Ebner. , ... the interview Frank Davis had with Kaylynn Chiarello-Ebner, about ... and fruit produce powders to kids meals, was successfully ...
(Date:7/29/2014)... HealthDay Reporter MONDAY, July ... that continues to rage throughout West Africa poses little risk ... spreads through physical touch, and it can,t be spread by ... director of the National Center for Emerging & Zoonotic Infectious ... explained in a Monday afternoon news conference. Those factors ...
Breaking Medicine News(10 mins):Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House Employees Volunteer at Local Rescue Mission 2Health News:The Discovery House Employees Volunteer at Local Rescue Mission 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:CDC Downplays Ebola's Threat to the United States 2Health News:CDC Downplays Ebola's Threat to the United States 3Health News:CDC Downplays Ebola's Threat to the United States 4
... each developed by Merck and Smith Glaxo Kline has found ... caused by the human papilloma viruses (HPVs). ... reduced infection in about 90% of the subjects. ... immunologic technologies have contributed to the discovery of the link ...
... revealed that having several older brothers increases the chances of ... //weight to the idea of a biological basis for sexual ... in St Catharines, Canada said, "It's likely to be a ... probably a biological basis for homosexuality." ,S Marc ...
... Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance ... a new oral drug option// to the group ... ,Celgene Corporation (Nasdaq: CELG) announced that the U.S. ... for its Supplemental New Drug Application (sNDA) for ...
... had stated on Friday that the precedent conditions of ... outbreak at Durban's Mahatma Gandhi Memorial Hospital, which had ... Mseleku said, “Nobody needs to communicate these problems. We ... It's (overcrowding and staff shortages) a known fact.” That ...
... by K M Shah Dental College an eye wash and ... admission //process by with a supposed entrance test held by ... for granting admissions. ,The court, had issued a ... admission should continue and has asked the Gujarat University (GU) ...
... Quebec say that chronic job stress can raise blood ... ,The research, appearing in the American Journal of ... deadlines increased blood pressure especially in men. The study ... study supports the hypothesis that job strain, particularly in ...
Cached Medicine News:Health News:Klebsiella Outbreak In Durban Blamed On Staff Shortage & Overcrowding 2Health News:Gujarat High Court Stays PG Admissions In A Private Dental Collage 2
... formula is the most convenient multi-purpose no ... one bottle without the need to rub: ... lenses and removes protein build-up when used ... contains Hydranate, a special ingredient that removes ...
Half Trial Frames with precision engineering and lightweight material....
Half Eye Trial Frame - Child...
Non Sterile surgical blade....
Medicine Products: